Assessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple Myeloma Patients
Status:
Recruiting
Trial end date:
2021-07-30
Target enrollment:
Participant gender:
Summary
Bortezomib considered the standard of care for treating multiple myeloma patients, we aimed
to assess the safety and efficacy of newly approved drug (Alvocade ®) in Iraq, in newly
diagnosed patients.